Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Lexington (Kentucky, USA) Piramal Pharma Ltd - 543635 - Submission Of Application For Re-Classification From 'Promoter Group' Category To 'Public' Category Of Piramal Pharma Limited ('The Company')
Submission of application for re-classification from 'Promoter Group' category to 'Public' category of Piramal Pharma Limited ('the Company') Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call with Investors/Analysts Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Conference Call on the financial results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2022 Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Read With Regulation 31A Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')
Disclosure under Regulation 30 read with Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations') - Re-classification of certain entities from 'Promoter Group' category to 'Public' category of Piramal Pharma Limited ('the Company') Piramal Pharma Ltd - 543635 - Report Of The Auditors On Financial Results For The Quarter And Nine Months Ended 31St December, 2022
Report of the Auditors on financial results for the Quarter and Nine months ended 31st December, 2022 Q3FY23 Quarterly Result Announced for Piramal Pharma Ltd.
Piramal Pharma announced Q3FY23 results: Q3FY23: Revenue from operation grew by 11% YoY in Q3FY23 and 9MFY23 EBITDA margin for Q3FY23 and 9MFY23 was 10% - impacted by higher operating expenses including raw material cost, energy prices, wage inflation and marketing cost Successfully cleared 29 regulatory inspections (including US FDA) and 155 customer audits in 9MFY23 New capabilities/capacity expansion gone live at Ahmedabad PDS, peptide facility (Turbhe, India) and Riverview (US) Nandini Piramal, Chairperson, Piramal Pharma Limited said, “Basis our recent increase in customer engagements and continued inflows of RFPs (Request for Proposals), we believe that the demand for CDMO services, especially for our differentiated offerings remain strong. We continue to maintain our quality track record with successful US FDA inspections at our Riverview facility. In our Complex Hospital Generic business, the Inhalation Anesthesia portfolio is seeing a healthy demand. Further, our India Consumer Healthcare business is delivering growth driven by power brands. Investment in e-commerce channels is also yielding good results. We believe in the potential of our business and in line with our aim to grow, the Board has approved the recommendation to allot equity shares for an amount not exceeding Rs 1,050 crore., subject to receipt of requisite regulatory approvals, market conditions and other considerations.” Result PDF Piramal Pharma Ltd - 543635 - Outcome Of The Meeting Of The Board Of Directors Of Piramal Pharma Limited (The 'Company') Held On 8Th February, 2023
We wish to inform you that, the board of directors of the Company ('Board'), at its meeting held today, 8th February, 2023, has inter alia considered and approved the following: Piramal Pharma Ltd - 543635 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Piramal Pharma Limited (The 'Company') Held On 8Th February, 2023
Outcome of the meeting of the board of directors of Piramal Pharma Limited (the'Company') held on 8th February, 2023 and intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations') Piramal Pharma Ltd - 543635 - Update on board meeting
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 ,inter alia, to consider and approve Update on board meeting of the Company ('Board') to consider, inter alia, the proposal of fund raising by way of equity shares or other securities through rights issue as may be permitted under applicable law, subject to such regulatory/statutory approvals as may be required.meeting